Bisoprolol vs Atenolol
Clinical Comparison
Clinical Context
Both are beta-1 selective blockers, but bisoprolol has largely replaced atenolol in modern practice. Bisoprolol has proven mortality benefit in heart failure (CIBIS-II), is more beta-1 selective, and is preferred for rate control in AF. Atenolol has fallen from favour for hypertension after the LIFE trial showed inferior stroke prevention.
Drug Profiles
Bisoprolol
Beta-1 selective adrenoceptor blocker
Mechanism
Highly selective beta-1 blocker, reducing heart rate, myocardial contractility, and cardiac output without significant beta-2 blockade
Indications
- Hypertension
- Chronic heart failure (stable)
- Rate control in atrial fibrillation
- Stable angina pectoris
Common Doses
HF: start 1.25 mg OD, titrate to 10 mg OD; Hypertension: 5-10 mg OD; AF rate control: 2.5-10 mg OD
Route
Oral
Onset & Duration
Onset 1-2 hours; half-life 10-12 hours; duration 24 hours
Atenolol
Beta-1 selective adrenoceptor blocker
Mechanism
Beta-1 selective blocker, reducing heart rate and cardiac output; less beta-1 selective than bisoprolol
Indications
- Hypertension
- Angina pectoris
- Rate control in arrhythmias
- Migraine prophylaxis (off-label)
Common Doses
25-50 mg OD; max 100 mg OD
Route
Oral, IV
Onset & Duration
Onset 1 hour; half-life 6-7 hours; clinical effect 24 hours
Key Differences
| Category | Bisoprolol | Atenolol |
|---|---|---|
| Heart failure evidence | Mortality benefit proven (CIBIS-II) | No proven mortality benefit in HF |
| Beta-1 selectivity | Most beta-1 selective beta-blocker available | Moderately beta-1 selective |
| Hypertension guidelines | Step 4 option per NICE NG136 | No longer recommended first-line (LIFE trial) |
| Elimination | 50% hepatic, 50% renal | Primarily renal — dose reduce in CKD |
| CNS effects | Moderate lipophilicity — some CNS penetration | Hydrophilic — less CNS penetration, fewer nightmares |
| IV formulation | No IV formulation available | IV available for acute situations |
Heart failure evidence
Mortality benefit proven (CIBIS-II)
No proven mortality benefit in HF
Beta-1 selectivity
Most beta-1 selective beta-blocker available
Moderately beta-1 selective
Hypertension guidelines
Step 4 option per NICE NG136
No longer recommended first-line (LIFE trial)
Elimination
50% hepatic, 50% renal
Primarily renal — dose reduce in CKD
CNS effects
Moderate lipophilicity — some CNS penetration
Hydrophilic — less CNS penetration, fewer nightmares
IV formulation
No IV formulation available
IV available for acute situations
Key Advantages
Bisoprolol
- Proven mortality benefit in heart failure (CIBIS-II trial)
- Most beta-1 selective — safer in mild asthma/COPD at low doses
- Once-daily dosing
- Well-tolerated with gradual titration
Atenolol
- IV formulation available for acute arrhythmias
- Well-established safety profile (decades of use)
- Renally excreted — no hepatic metabolism
- Low CNS penetration — fewer nightmares/insomnia
Key Cautions
Bisoprolol
- Still avoid in severe asthma
- Fatigue, cold extremities, and sexual dysfunction
- Do not stop abruptly — risk of rebound tachycardia
- Mask hypoglycaemia symptoms in diabetics
- Bradycardia — monitor heart rate
Atenolol
- No proven mortality benefit in heart failure
- Dose reduction needed in renal impairment
- Less beta-1 selective than bisoprolol
- Not recommended as first-line for hypertension by NICE (LIFE trial: inferior to losartan for stroke prevention)
Clinical Verdict
Bisoprolol is the preferred beta-blocker for heart failure, AF rate control, and most indications. Atenolol has a role when IV access is needed or in patients with renal-only clearance needs, but is otherwise second choice.
Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).
Full monographs for Bisoprolol & Atenolol in the MedNext app
Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.
Download MedNext Formulary